Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991037 | 0.84 | SIGMAR1 (0.40) | KMT2AMEN1LMNASIGMAR1CA12 | |
| SCHEMBL6293449 | 0.82 | SIGMAR1 (0.46) | LTA4HSIGMAR1 | |
| SCHEMBL23113743 | 0.81 | HRH3 (0.47) | CYP2C19ALDH1A1KDM4ESIGMAR1MC4R | |
| SCHEMBL845155 | 0.81 | HRH3 (0.52) | CYP2C19ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL61472 | 0.80 | MC4R (0.62) | LMNANPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL27729397 | 0.80 | HRH3 (0.50) | CYP2C19ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL161004 | 0.80 | HRH3 (0.55) | CYP2C19ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL2064262 | 0.80 | KMT2A (0.64) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL3319068 | 0.79 | KMT2A (0.68) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL27729240 | 0.78 | HRH3 (0.53) | CYP2C19ALDH1A1KDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897644-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | claimed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | claimed |
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| EP-3897644-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-107428749-B | Substituted imidazo [1,2- α ] pyridin-2-ylamine compounds, pharmaceutical compositions and methods of use thereof | 上海复旦张江生物医药股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | KMT2A 4140/4885MEN1 1708/4885LMNA 4074/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | KMT2A 4140/4885MEN1 1708/4885LMNA 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.